nkg2d car-t cell
Cell therapyexperimental
Clinical trial activity
6 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2020 (NCT04270461)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - KLRK1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07021534 | Phase 1 | Jun 10, 2025 | Zhejiang University |
| NCT04717999 | N/A | Sep 1, 2021 | UWELL Biopharma |
| NCT05131763 | Phase 1 | Mar 1, 2021 | Fudan University, KAEDI, Xunyang Changchun Shihua Hospital |
| NCT04658004 | Early Phase 1 (Phase 1) | Jan 15, 2021 | Yake Biotechnology Ltd., Zhejiang University |
| NCT04324996 | Phase 1/Phase 2 (Phase 2) | Mar 21, 2020 | Government of China |
| NCT04270461 | Phase 1 | Mar 1, 2020 | Jiujiang University, KAEDI |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KAEDI | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Government of China | Government | 1 | 1 | 1 | 2020 |
| Jiujiang University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| UWELL Biopharma | For profit | 1 | 1 | 1 | 2021 |
| Xunyang Changchun Shihua Hospital | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Yake Biotechnology Ltd. | Government | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1